9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

IGFBP 4 Human

Insulin-Like Growth Factor Binding Protein-4 Human
GRF0176

Product Overview

Name	IGFBP 4 Human

Description

Insulin-Like Growth Factor Binding Protein-4 Human

Accession (Primary)	P22692

Synonyms

IGFBP-5, IBP-5, IGF-binding protein 5.

Introduction

IGFBP5 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Source

Escherichia Coli.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation

IBP-5 was lyophilized from a concentrated (1mg/ml) solution containing 10mM sodium Citrate pH-3.

Stability

Lyophilized IBP5 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IGFBP 5 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Purity

Greater than 96.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.

Amino acid sequence

LGSFVHCEPC DEKALSMCPP SPLGCELVKE PGCGCCMTCA LAEGQSCGVY TERCAQGLRC LPRQDEEKPL HALLHGRGVC LNEKSYREQV KIERDSREHE EPTTSEMAEE TYSPKIFRPK HTRISELKAE AVKKDRRKKL TQSKFVGGAE NTAHPRIISA PEMRQESEQG PCRRHMEASL QELKASPRMV PRAVYLPNCD RKGFYKRKQC

9051 Mira Mesa Blvd, #910094
San Diego, CA 92191
Tel: 760-390-3989

KPSRGRKRGI CWCVDKYGMK LPGMEYVDGD FQCHTFDSSN VE.

Biological Activity

Solubility

It is recommended to reconstitute the lyophilized Insulin-Like Growth Factor Binding Protein-5 in sterile 18M?-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

References

Title :Effects of Dietary Carbohydrate Modification in Persons with the Metabolic Syndrome - A Transcriptomics Approach in Adipose Tissue Publication :Department of Clinical Nutrition, Food and Health Research Centre Institute of Public Health and Clinical Nutrition Faculty of Health Sciences University of Eastern Finland Kuopio 2010 Link : IGFBP 5 prospec publication

Precautions

IGFBP 4 Human is for research use only and not for use in diagnostic or therapeutic procedures.

Target Information: (P22692)